Mangoceuticals, Inc.
MGRX
$4.91
-$0.37-7.01%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 755.10K | 866.90K | 844.90K | 731.50K | 496.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 755.10K | 866.90K | 844.90K | 731.50K | 496.00K |
| Cost of Revenue | 312.60K | 362.50K | 323.20K | 300.00K | 202.30K |
| Gross Profit | 442.50K | 504.40K | 521.70K | 431.50K | 293.80K |
| SG&A Expenses | 7.98M | 8.08M | 8.34M | 8.66M | 7.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -541.70K | -541.70K |
| Total Operating Expenses | 8.34M | 8.50M | 8.55M | 8.27M | 6.96M |
| Operating Income | -7.59M | -7.63M | -7.70M | -7.54M | -6.46M |
| Income Before Tax | -9.33M | -9.13M | -9.02M | -9.21M | -7.32M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.33 | -9.13 | -9.02 | -9.21 | -7.32 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 800.00 | 300.00 | 0.00 | -- | -- |
| Net Income | -9.33M | -9.13M | -9.02M | -9.21M | -7.32M |
| EBIT | -7.59M | -7.63M | -7.70M | -7.54M | -6.46M |
| EBITDA | -7.57M | -7.61M | -7.68M | -7.52M | -6.45M |
| EPS Basic | -5.88 | -6.58 | -7.38 | -9.24 | -8.03 |
| Normalized Basic EPS | -3.67 | -4.11 | -4.61 | -5.77 | -5.02 |
| EPS Diluted | -5.88 | -6.58 | -7.38 | -9.24 | -8.03 |
| Normalized Diluted EPS | -3.67 | -4.11 | -4.61 | -5.77 | -5.02 |
| Average Basic Shares Outstanding | 6.59M | 5.64M | 4.95M | 4.18M | 3.76M |
| Average Diluted Shares Outstanding | 6.59M | 5.64M | 4.95M | 4.18M | 3.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
